Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Income from Continuing Operations (2018 - 2025)

10x Genomics' Income from Continuing Operations history spans 8 years, with the latest figure at 16252000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 66.85% year-over-year to 16252000.0; the TTM value through Dec 2025 reached 43544000.0, up 76.16%, while the annual FY2025 figure was 43544000.0, 76.16% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 16252000.0 at 10x Genomics, up from 27472000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 34538000.0 in Q2 2025 and bottomed at 92986000.0 in Q3 2023.
  • The 5-year median for Income from Continuing Operations is 36825000.0 (2024), against an average of 35274650.0.
  • The largest annual shift saw Income from Continuing Operations crashed 483.22% in 2022 before it soared 191.14% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 18449000.0 in 2021, then increased by 6.69% to 17215000.0 in 2022, then plummeted by 184.36% to 48952000.0 in 2023, then decreased by 0.16% to 49028000.0 in 2024, then soared by 66.85% to 16252000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXG's Income from Continuing Operations are 16252000.0 (Q4 2025), 27472000.0 (Q3 2025), and 34538000.0 (Q2 2025).